We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Tilray, Inc. (TLRY - Free Report) closed at $12.17 in the latest trading session, marking a +1.33% move from the prior day. This move outpaced the S&P 500's daily loss of 0.91%.
Coming into today, shares of the company had lost 5.28% in the past month. In that same time, the Medical sector lost 0.52%, while the S&P 500 gained 0.01%.
TLRY will be looking to display strength as it nears its next earnings release.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.14 per share and revenue of $785.29 million, which would represent changes of +69.57% and +166.34%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for TLRY. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. TLRY is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 197, which puts it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
Tilray, Inc. (TLRY - Free Report) closed at $12.17 in the latest trading session, marking a +1.33% move from the prior day. This move outpaced the S&P 500's daily loss of 0.91%.
Coming into today, shares of the company had lost 5.28% in the past month. In that same time, the Medical sector lost 0.52%, while the S&P 500 gained 0.01%.
TLRY will be looking to display strength as it nears its next earnings release.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.14 per share and revenue of $785.29 million, which would represent changes of +69.57% and +166.34%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for TLRY. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. TLRY is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 197, which puts it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.